Literature DB >> 21427495

Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection.

Ghader Khalili1, Faramarz Dobakhti, Hamid Mahmoudzadeh-Niknam, Vahid Khaze, Fatemeh Partovi.   

Abstract

BACKGROUND: Leishmaniasis is a complex disease which presents as visceral, cutaneous and mucocutaneous forms. The current treatment options for this infection are very limited and the immunological state of the host appears to play an important role in the efficacy of the treatment. Immunostimulation through immune response activating agents such as Imiquimod is another rational approach for this purpose.
OBJECTIVE: We assessed the efficacy of immunotherapy with Imiquimod alone or combined with Glucantime for treatment of Leishmania major infection in BALB/c mice.
METHODS: Treatment efficacy was monitored by determination of thickness and parasite load of infected footpad of mice.
RESULTS: The footpad thickness revealed that treatment with Imiquimod plus Glucantime has the highest efficacy. The results were confirmed by parasite load of infected footpad. Our data shows that treatment of Leishmania major infection in BALB/c mice by the combined Imiquimod and Glucantime is more efficient than each drug alone.
CONCLUSION: The combination of Imiquimod with chemotherapy may offer a way for more efficient treatment of leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21427495     DOI: IJIv8i1A6

Source DB:  PubMed          Journal:  Iran J Immunol        ISSN: 1735-1383            Impact factor:   1.603


  5 in total

Review 1.  Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development.

Authors:  Shyam Sundar; Neha Agrawal; Bhawana Singh
Journal:  Expert Opin Drug Metab Toxicol       Date:  2019-06-17       Impact factor: 4.481

2.  Cutaneous Leishmaniasis: Current Treatment Practices in the USA for Returning Travelers.

Authors:  Daniel P Eiras; Laura A Kirkman; Henry W Murray
Journal:  Curr Treat Options Infect Dis       Date:  2015-03-01

3.  Cytokine Effect of TLR3, TLR4, and TLR7 Agonists Alone or Associated with Leishmania infantum Antigen on Blood from Dogs.

Authors:  Pamela Martínez-Orellana; Sara Montserrat-Sangrà; Paulina Quirola-Amores; Noemí González; Laia Solano-Gallego
Journal:  Biomed Res Int       Date:  2018-11-12       Impact factor: 3.411

Review 4.  Therapeutic advances in the topical treatment of cutaneous leishmaniasis: A review.

Authors:  Marium Azim; Saeed Ahmad Khan; Saleem Ullah; Shafiq Ullah; Syed Ishtiaq Anjum
Journal:  PLoS Negl Trop Dis       Date:  2021-03-03

5.  Efficacy of imiquimod 5% cream as first-line management in cutaneous leishmaniasis caused by Leishmania mexicana.

Authors:  Gabriela Fuentes-Nava; Andrés Tirado-Sánchez; Edith A Fernández-Figueroa; Sokani Sánchez-Montes; Ingeborg Becker; Alexandro Bonifaz
Journal:  Rev Soc Bras Med Trop       Date:  2021-03-22       Impact factor: 1.581

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.